GLP-1 weight regain after stopping: what the data really shows

What did @cbcnews actually say?

CBC News reported on a BMJ study finding that people who stopped GLP-1 medications regained "just under a pound per month" and were "projected to return to their original weight within nearly two years." They also noted that health benefits like lower cholesterol and blood pressure reversed after stopping, and that people who quit lifestyle programs also regained weight, just more slowly. The framing was largely accurate and sourced, though a few details deserve scrutiny.

The video leaned on a real patient experience, Heather White stopping Ozempic after seven months due to nausea and digestive issues, to illustrate the dropout problem. That personal narrative is consistent with what the data actually shows about side-effect-driven discontinuation.

Does the science back this up?

Largely, yes. The BMJ systematic review they referenced is almost certainly the Sargeant et al. (2024, BMJ) analysis comparing post-discontinuation weight trajectories across GLP-1 trials and lifestyle intervention trials. That paper found weight regain after stopping GLP-1s was substantially faster than after stopping behavioral programs.

The "just under a pound per month" figure aligns with data from the STEP 4 trial (Rubino et al., 2021, JAMA), which found participants who switched from semaglutide to placebo regained roughly two-thirds of their lost weight within 48 weeks. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) for tirzepatide showed similar rebound patterns. The two-year return-to-baseline projection is a modeled estimate, not a directly observed finding in most studies, and CBC News does acknowledge this briefly.

The claim that about half of GLP-1 users quit within one year is also backed up. A 2023 analysis by Hampp et al. published in Obesity found one-year persistence rates for semaglutide hovering around 40 to 50 percent in real-world settings, depending on indication and insurance coverage.

What did they get wrong, or right?

They got the core findings right. Where the video is weaker is context. Saying people "were projected" to return to baseline in two years is doing a lot of work. That projection comes from extrapolating short-term regain rates, and most of the included studies ran for under a year, which the video does mention briefly at the end. Credit for that caveat, but it deserved more emphasis, not a throwaway line.

The comparison to lifestyle programs is genuinely useful framing and often gets left out of GLP-1 coverage. Giving it airtime was the right editorial call.

One thing the video glosses over: not everyone regains all the weight. Some patients maintain partial losses, particularly those who make concurrent lifestyle changes. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed meaningful weight maintenance in a subset of semaglutide users even after two years. The "return to original weight" headline is accurate on average but obscures real individual variation.

What should you actually know?

GLP-1 medications appear to work, for most people, as long-term treatments rather than finite courses. The biology here matters. These drugs reduce appetite partly by acting on brain receptors involved in hunger signaling. When you stop the drug, those effects stop. That is not a character flaw or a willpower failure. It is pharmacology.

If you stopped a GLP-1 because of side effects, cost, or access issues, that is an extremely common situation. The dropout rates in real-world data are not a niche problem. Insurance coverage gaps, compounding drug supply issues, and gastrointestinal side effects are all documented barriers. The video names these correctly.

What the video does not say, but is worth knowing: switching medications is a legitimate clinical option. Not everyone responds the same way to every GLP-1 agent. Liraglutide, semaglutide, and tirzepatide have meaningfully different tolerability profiles for different patients. That conversation belongs with a licensed clinician who knows your history, not a TikTok comment section.

Bottom line: Is this worth sharing?

Yes, with a caveat. CBC News did responsible work here. They cited a real peer-reviewed paper, included an important comparison group, and avoided the hype that dominates most GLP-1 content. The two-year projection deserved a stronger asterisk, and individual variation got buried. But this is solidly above-average health journalism for a short-form video. The core message, that stopping these medications tends to reverse their benefits, is well-supported by multiple independent trials.